Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT Jr +: Long-term Safety of Efgartigimod in Children With Generalized Myasthenia Gravis
NCT05374590Phase 3Enrolling by invitation
- Sponsor
- argenx
- Start
- Aug 2022
- Primary completion
- Sep 2029
- Modality
- Antibody Fragments
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by argenx. Primary endpoint: Adverse Events at 4 years. Started Aug 2022; status: enrolling by invitation.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT05374590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05374590.